Benitec Biopharma (BNTC) Return on Capital Employed (2020 - 2025)
Benitec Biopharma (BNTC) posted Return on Capital Employed of 34.4% for Q4 2025, up 28.02% sequentially from 47.79% in Q3 2025, and up 271.0% YoY from 9.27% in Q4 2024.
Benitec Biopharma (BNTC) Return on Capital Employed (2020 - 2025) Analysis & Trends
Benitec Biopharma has reported Return on Capital Employed for 6 years, with the latest figure at 34.4% in Q4 2025.
- Quarterly Return on Capital Employed rose 271.0% year-over-year to 34.4% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 34.4% (up 271.0% YoY) and the FY2025 annual result came in at 56.36%, up 3969.0% from the prior year.
- Return on Capital Employed advanced to 34.4% in Q4 2025 per BNTC's latest filing, from 47.79% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 34.4% in Q4 2025 and troughed at 807.15% in Q2 2023.
- A 5-year average of 167.19% and a median of 123.12% in 2021 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed plunged 48171 bps in 2023, then jumped 72873 bps in 2024.
- Over 5 years, Return on Capital Employed stood at 128.71% in 2021, then fell by 14 bps to 146.86% in 2022, then increased by 20 bps to 117.53% in 2023, then jumped by 68 bps to 37.11% in 2024, then gained by 7 bps to 34.4% in 2025.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 34.4%, 47.79%, and 37.11% for Q4 2025, Q3 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Benitec Biopharma | 577.39 Mn | 388.49 Mn | - | -34.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -34.40% |
| Sep 30, 2025 | -47.79% |
| Dec 31, 2024 | -37.11% |
| Sep 30, 2024 | -40.06% |
| Jun 30, 2024 | -78.42% |
| Mar 31, 2024 | -145.82% |
| Dec 31, 2023 | -117.53% |
| Sep 30, 2023 | -181.52% |
| Jun 30, 2023 | -807.15% |
| Mar 31, 2023 | -278.88% |
| Dec 31, 2022 | -146.86% |
| Sep 30, 2022 | -194.99% |
| Jun 30, 2022 | -325.44% |
| Mar 31, 2022 | -167.54% |
| Dec 31, 2021 | -128.71% |
| Sep 30, 2021 | -87.35% |
| Jun 30, 2021 | -84.80% |
| Mar 31, 2021 | -105.01% |
| Dec 31, 2020 | -95.73% |
| Sep 30, 2020 | -106.14% |